---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000209"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:34:46.362869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY

## Summary
- 2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.
- Q4 2024 net sales $7.1M vs $4.8M Q4 2023; Q4 operating loss $1.0M vs $3.4M.
- Sales & marketing expense fell to 47% of net sales for FY2024, down from 64% in 2023.
- Merger with Aditxt: $1.5M funding due by Apr 7, 2025; stockholder meeting by Sep 26, 2025; close by Sep 30, 2025.
- Raised $2.7M from Aditxt in Oct 2024; used to pay FDA obligations; year-end restricted cash $0.7M.

## SEC filing metadata
- accession: 0001641172-25-000209
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/0001641172-25-000209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000209
- JSON: https://secwatch.observer/filing/0001641172-25-000209.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000209.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.